Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Tenaya Therapeutics Inc. (NASDAQ: TNYA) announced that it has granted stock options to its new Chief Financial Officer, Eric Hyllengren, to purchase 1,650,000 shares of Tenaya common stock. Additionally, options for an aggregate of 187,200 shares were granted to two new non-executive employees. These grants were made as an inducement for the employees to accept employment with Tenaya, in accordance with NASDAQ Listing Rule 5635(c)(4). The stock options have an exercise price of $0.8365 per share, equal to the closing price on July 13, 2026, a ten-year term, and will vest over four years. Tenaya Therapeutics is a clinical-stage biotechnology company focused on developing therapies for heart disease.